AzTrials
AzTrials

Osteoarthritis of the KneePhase 2NCT02068599

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

A Phase 2 study testing TV-45070 in people with Osteoarthritis of the Knee, run by Teva Branded Pharmaceutical Products R&D, Inc. at 42 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single knee Read more about this study

Who is it for?
Ages 40 to 85 years
Conditions the study is for
Osteoarthritis of the Knee
What is being tested?
TV-45070
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
389 participants
Where
42 sitesUnited States
Study dates
14 Apr 2014to 4 May 2015
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient is between 40 and 85 years of age, Patient has primary OA in a single knee (target knee) confirmed by American College of Rheumatology criteria.
  • For patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics at the time of the screening visit,
  • Patient has visual analog scale (VAS) pain scores with acceptable ranges as determined by the investigator during screening
  • Except for OA, patient is judged by the investigator to be medically healthy and able to participate in the study.
  • Other criteria apply, please contact the investigator for additional information

Who cannot join

  • Patient has secondary or inflammatory arthritis of the knee such as psoriasis, rheumatoid arthritis (RA), gout, other primary bone disease, or acute trauma.
  • Patient has symptomatic chondrocalcinosis
  • Patient has a history of fibromyalgia.
  • Patient has any painful or disabling conditions that in the opinion of the investigator may confound assessment of pain scoring.
  • Patient has uncontrolled cardiac, renal, hepatic or other systemic disorders that in the opinion of the investigator may jeopardize the patient.
  • Patient has significant edema or skin disorder (including sores, rashes, or ulcers) at the target knee and surrounding area.
Show all 12Show fewer
  • Patient has a history of total or partial knee replacement in either leg.
  • Patient had a major reconstructive knee surgery or arthroscopy of the target knee within 6 months before the screening visit.
  • Patient is unable or unwilling to discontinue opioid and/or other prescription analgesics for control of OA pain.
  • Patient is intolerant to study drug, its excipients, and/or acetaminophen.
  • Patient uses any over the counter oral medications such as glucosamine or chondroitin sulfate products, unless the patient has been receiving the medication for ≥3 months at the time of the screening visit and maintains the medication as stable therapy for the duration of the study.
  • Other criteria apply, please contact the investigator for additional information

Trial locations and contacts

42 sites in 1 country.

42 sites in 1 country

United States42 sites
  • Teva Investigational Site 12217

    Anaheim, California

  • Teva Investigational Site 12244

    Anaheim, California

  • Teva Investigational Site 12253

    Atlanta, Georgia

  • Teva Investigational Site 12228

    Bingham Farms, Michigan

  • Teva Investigational Site 12252

    Cerritos, California

  • Teva Investigational Site 13009

    Cerritos, California

  • Teva Investigational Site 12239

    Charlotte, North Carolina

  • Teva Investigational Site 12222

    Charlottesville, Virginia

  • Teva Investigational Site 12224

    Cincinnati, Ohio

  • Teva Investigational Site 12256

    Clearwater, Florida

  • Teva Investigational Site 12232

    Dallas, Texas

  • Teva Investigational Site 12241

    DeLand, Florida

  • Teva Investigational Site 12233

    El Cajon, California

  • Teva Investigational Site 12246

    Eustis, Florida

  • Teva Investigational Site 12243

    Evansville, Indiana

  • Teva Investigational Site 12231

    Fort Myers, Florida

  • Teva Investigational Site 12242

    Hazelwood, Missouri

  • Teva Investigational Site 12216

    Hialeah, Florida

  • Teva Investigational Site 12230

    Jacksonville, Florida

  • Teva Investigational Site 12240

    Lomita, California

  • Teva Investigational Site 12250

    Marietta, Georgia

  • Teva Investigational Site 12236

    Memphis, Tennessee

  • Teva Investigational Site 12220

    Miami, Florida

  • Teva Investigational Site 12218

    New Orleans, Louisiana

  • Teva Investigational Site 12219

    New York, New York

  • Teva Investigational Site 12221

    Oldsmar, Florida

  • Teva Investigational Site 12223

    Omaha, Nebraska

  • Teva Investigational Site 12226

    Orlando, Florida

  • Teva Investigational Site 12237

    Orlando, Florida

  • Teva Investigational Site 12255

    Ormond Beach, Florida

  • Teva Investigational Site 12238

    Overland Park, Kansas

  • Teva Investigational Site 12227

    Plano, Texas

  • Teva Investigational Site 12225

    Plantation, Florida

  • Teva Investigational Site 12248

    Raleigh, North Carolina

  • Teva Investigational Site 12251

    Sacramento, California

  • Teva Investigational Site 12229

    Sanford, Florida

  • Teva Investigational Site 12234

    Spring Valley, California

  • Teva Investigational Site 12249

    St Louis, Missouri

  • Teva Investigational Site 12235

    Tampa, Florida

  • Teva Investigational Site 12245

    Watertown, Massachusetts

  • Teva Investigational Site 12247

    Winston-Salem, North Carolina

  • Teva Investigational Site 12254

    Winston-Salem, North Carolina

Other trials in United States

About this study

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Primary Osteoarthritis Affecting a Single Knee

The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single knee

Being tested
TV-45070, Placebo
Keywords
Osteoarthritis, OA, Arthritis pain
Medical subject headings
Osteoarthritis, Knee, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TV-45070Drug

    Also called funapide, XEN402

    TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.

  • PlaceboDrug

    Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.

Study groups in NCT02068599
Study groupRoleWhat they receive
TV-45070 4%ExperimentalTV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
Receives: Drug: TV-45070
TV-45070 8%ExperimentalTV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
Receives: Drug: TV-45070
PlaceboPlacebo comparatorPlacebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)

    The Western Ontario and McMasters Universities Arthritis Index [WOMAC] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain [5 items], stiffness [2 items], and physical function [17 items]). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor.

    Measured: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)

Secondary outcomes (10)
  1. Change From Baseline to Last 5 Days of Treatment in the Average Daily WOMAC Pain Subscale Score In the Target Knee Using a Mixed Model for Repeated Measures

    The five items in the WOMAC Pain Subscale cover pain during walking, using stairs, in bed, sitting or lying, and standing. Daily WOMAC pain subscale score is calculated as the sum of the 5-item pain subscale scores (WOMAC) recorded at evening for a total range of 0 (no pain) to 500 (worst pain on all 5 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC scores for the 5-item pain subscale as a covariate; and patient as a random factor.

    Measured: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)

  2. Change From Baseline to Last 5 Days of Treatment in the Average Morning Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)

    The Western Ontario and McMasters Universities Arthritis Index [WOMAC] is a widely used, validated, patient-reported questionnaire used to assess pain, stiffness, and physical function in patients with OA of the knee. It consists of 24 items separated into 3 domains (pain [5 items], stiffness [2 items], and physical function [17 items]). The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. Participants record their response to WOMAC Question 1 in the study diary based on average pain upon walking since the last assessment or over the past 12 hours. Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average morning WOMAC Question 1 score as a covariate; and patient as a random factor.

    Measured: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)

  3. Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Physical Function Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures

    The seventeen items in the WOMAC physical function subscale cover stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. WOMAC physical function subscale score is calculated as the sum of the 17-item physical function subscale scores (WOMAC) for a total range of 0 (no pain) to 1700 (worst pain on all 17 items). Negative change from baseline scores indicate improvement in pain. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline physical function WOMAC scores for the 17-item subscale as a covariate; and patient as a random factor.

    Measured: Baseline (day 1, predose), Treatment: Week 4 (day 29)

  4. Change From Baseline (Randomization Visit) to the Week 4 Visit in the WOMAC Stiffness Subscale Score for the Target Knee Using a Mixed Model for Repeated Measures

    The two items in the WOMAC stiffness subscale cover stiffness after first waking and later in the day. WOMAC stiffness subscale score is calculated as the sum of the 2-item stiffness subscale scores (WOMAC) for a total range of 0 (no stiffness) to 200 (worst stiffness on both items). Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline stiffness WOMAC scores for the 2-item subscale as a covariate; and patient as a random factor.

    Measured: Baseline (day 1, predose), Treatment: Week 4 (day 29)

  5. Percentage of Participants With a >=30% and a >=50% Response in Average Evening Pain Intensity of WOMAC Question 1 in the Target Knee During the Last 5 Days of Treatment Compared With Baseline

    WOMAC Question 1 is the first question in the pain domain and asks patients to rate their pain in the target knee while walking on a flat surface. The possible score for each item ranges from 0 (no pain) to 100 mm (worst pain). Average pain is calculated using a MMRM which includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline average evening WOMAC Question 1 score as a covariate; and patient as a random factor. Responder rate was calculated as 100 * the value of (average WOMAC pain subscale during the last 5 days of treatment [Days 24 to 28]) - average WOMAC pain subscale at baseline [the 5 days prior to randomization])/average WOMAC pain subscale at baseline (the 5 days prior to randomization). Participants with missing responder rates were treated as nonresponders.

    Measured: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)

  6. Change From Baseline (Randomization Visit) to the Week 4 Visit in the Pain Quality Assessment Scale - Revised (PQAS-R) for the Target Knee Using a Mixed Model for Repeated Measures

    PQAS-R is a standardized self-report tool that measures various aspects of a participant's pain. There are 19 questions (question 19 has 2 parts) that ask the participant to rate the various aspects (intensity, sharpness, heat, cold, etc.) of his/her pain over the past week on average on a scale of 0 to 10 (0 = not [aspect] and 10 = the most or worst imaginable [aspect]). PQAS-R score at each visit is the sum of responses for the 19 questions for a total range of 0=no pain to 200=worst imaginable pain in all aspects. Negative change from baseline scores indicate improvement in stiffness. MMRM includes week, treatment, study center, and treatment by week interaction as fixed factors; baseline PQAS-R score for the 19 questions (20 parts) as a covariate; and patient as a random factor.

    Measured: Baseline (day 1, predose), Treatment: Week 4 (day 29)

  7. Participants' Global Assess of Treatment as Measured by the Patient Global Impression of Change (PGIC) at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)

    PGIC is a standardized self-report tool that measures the change in a participants overall status rating since the start of treatment on 7-point scale. The 7-point scale is defined as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors and unconstructed variance-covariance structure.

    Measured: Weeks 2 (day 15), 4 (day 29)

  8. Change From Baseline in the Patient Global Assessment (PGA) Scores at Weeks 2 and 4 Using a Mixed Model for Repeated Measures (MMRM)

    PGA is a simple self-report tool for measuring the overall way arthritis is affecting the patient at a particular point in time. There is 1 question and the response is provided on a visual analog scale (VAS) from 0 (very poor) to 100 (very good). The question is: Considering all the ways your arthritis affect you, how are you feeling today? Positive change from baseline scores indicate improvement. The MMRM model includes week, treatment, study center, and treatment by week interaction as the fixed factors; baseline PGA score as a covariate and unconstructed variance-covariance structure.

    Measured: Baseline (day 1, predose), Week 2 (day 15) and Week 4 (day 29)

  9. Percentage of Participants Who Are Responders Per Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 4

    Participants are classified as 'Yes' if the following criteria are met: - >=50% improvement from baseline and an absolute change >=20 on a scale of 1-100 in either the pain or physical function subscale (WOMAC). or 2 of the 3 criteria as below met: - 1) >=20% improvement from baseline and an absolute change >=10 on a scale of 1-100 in the pain subscale (WOMAC); - 2) >=20% improvement from baseline and an absolute change >=10 on a scale of 1-100 in the physical function subscale (WOMAC); - 3) at least a 20% improvement from baseline and an absolute change >=10 on a scale of 1-100 in PGA. Otherwise, 'No' The responder rate per OMERACT-OARSI criteria was analyzed using a generalized estimating equation (GEE) method, where binary variable responder rate (Yes/No) was modeled through logit link function, with treatment, center, week, and treatment*week as explanatory factors. The unstructured working correlation structure was applied.

    Measured: Week 4 (day 29)

  10. Participants With Treatment-Emergent Adverse Events

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Measured: day 1 up to day 57

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2014 (estimated)
  2. Study start14 Apr 2014
  3. Primary completion6 Apr 2015
  4. Study completion4 May 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
389 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02068599
Sponsor's protocol ID
TV-45070-CNS-20005
Status last verified
Nov 2021
First submitted
19 Feb 2014
Last updated
9 Nov 2021
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing TV-45070 in people with Osteoarthritis of the Knee, run by Teva Branded Pharmaceutical Products R&D, Inc. at 42 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Oct 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM) (time frame: Baseline (day -5 to day -1), Last 5 days of treatment (day 24 to day 28)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in